Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for chronic kidney disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronickidneydisease Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronickidneydisease Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronickidneydisease Fabrizi F, Dixit V, Magnini M, Elli A, Martin P CRD summary This review compared the administration of HBV vaccination through (...) for practice. Research: Further controlled trials are required to ascertain if the greater seroprotection rates associated with ID vaccination results in reduced incidence of de novo HBV amongst CKD patients. Future trials should also seek to improve their methodological quality. Funding Project Glomerulonephritis. Bibliographic details Fabrizi F, Dixit V, Magnini M, Elli A, Martin P. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronickidneydisease
Anaemia management in people with chronickidneydisease Anaemia management in people with chronickidneydisease Anaemia management in people with chronickidneydisease National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Anaemia management in people (...) with chronickidneydisease. London: National Institute for Health and Clinical Excellence (NICE). Clinical Guideline 39. 2006 Authors' objectives The aim of this guideline is to assess the management of anaemia in people with chronickidneydisease. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Anemia /therapy; ChronicDisease; KidneyDiseases /complications; Renal Insufficiency, Chronic Language Published English Country of organisation England Address for correspondence MidCity
Mircera for anaemia associated with chronickidneydisease: horizon scanning technology briefing Mircera for anaemia associated with chronickidneydisease: horizon scanning technology briefing Mircera for anaemia associated with chronickidneydisease: horizon scanning technology briefing NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NHSC. Mircera for anaemia associated with chronickidneydisease: horizon scanning technology briefing. Birmingham: National Horizon Scanning Centre (NHSC). 2006 Authors' objectives This study examines the use of Mircera for anaemia associated with chronickidneydisease. Timeliness warning Available on request from NHSC. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anemia /drug therapy; KidneyDiseases /complications Language Published English Country
Normalization of hemoglobin level in patients with chronickidneydisease and anemia. Whether correction of anemia in patients with stage 3 or 4 chronickidneydisease improves cardiovascular outcomes is not established.We randomly assigned 603 patients with an estimated glomerular filtration rate (GFR) of 15.0 to 35.0 ml per minute per 1.73 m2 of body-surface area and mild-to-moderate anemia (hemoglobin level, 11.0 to 12.5 g per deciliter) to a target hemoglobin value in the normal range (13.0 (...) =0.03). General health and physical function improved significantly (P=0.003 and P<0.001, respectively, in group 1, as compared with group 2). There was no significant difference in the combined incidence of adverse events between the two groups, but hypertensive episodes and headaches were more prevalent in group 1.In patients with chronickidneydisease, early complete correction of anemia does not reduce the risk of cardiovascular events. (ClinicalTrials.gov number, NCT00321919
Correction of anemia with epoetin alfa in chronickidneydisease. Anemia, a common complication of chronickidneydisease, usually develops as a consequence of erythropoietin deficiency. Recombinant human erythropoietin (epoetin alfa) is indicated for the correction of anemia associated with this condition. However, the optimal level of hemoglobin correction is not defined.In this open-label trial, we studied 1432 patients with chronickidneydisease, 715 of whom were randomly assigned
Chronickidneydisease and automatic reporting of estimated glomerular filtration rate: a position statement Chronickidneydisease and automatic reporting of estimated glomerular filtration rate: a position statement | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset close Individual Login Purchase options Connect (...) person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Chronickidneydisease and automatic reporting of estimated glomerular filtration rate: a position statement Timothy H Mathew, The Australasian Creatinine Consensus Working Group Med J Aust 2005; 183 (3): 138-141. || doi: 10.5694/j.1326-5377.2005.tb06958.x Published online: 1 August 2005 Topics Abstract The systematic staging of chronickidneydisease (CKD) by glomerular filtration measurement
Apolipoprotein E and progression of chronickidneydisease. Apolipoprotein E (APOE) genetic variation has been implicated in diabetic nephropathy with the epsilon2 allele increasing and the epsilon4 allele decreasing risk. APOE allelic associations with chronickidneydisease beyond diabetic nephropathy are unknown, with no studies reported in high-risk African American populations.To quantify the risk of chronickidneydisease progression associated with APOE in a population-based study (...) including white, African American, diabetic, and nondiabetic individuals.Prospective follow-up (through January 1, 2003) of Atherosclerosis Risk in Communities (ARIC) study participants, including 3859 African American and 10,661 white adults aged 45 to 64 years without severe renal dysfunction at baseline in 1987-1989, sampled from 4 US communities.Incident chronickidneydisease progression, defined as hospitalization or death with kidneydisease or increase in serum creatinine level of 0.4 mg/dL (35
Cardiovascular mortality risk in chronickidneydisease: comparison of traditional and novel risk factors. Elderly persons with chronickidneydisease have substantial risk for cardiovascular mortality, but the relative importance of traditional and novel risk factors is unknown.To compare traditional and novel risk factors as predictors of cardiovascular mortality.A total of 5808 community-dwelling persons aged 65 years or older living in 4 communities in the United States participated (...) in the Cardiovascular Health Study cohort. Participants were initially recruited from 1989 to June 1990; an additional 687 black participants were recruited in 1992-1993. The average length of follow-up in this longitudinal study was 8.6 years.Cardiovascular mortality among those with and without chronickidneydisease. Chronickidneydisease was defined as an estimated glomerular filtration rate of less than 60 mL/min per 1.73 m2.Among the participants, 1249 (22%) had chronickidneydisease at baseline
Chronickidneydisease: the global challenge. The worldwide rise in the number of patients with chronickidneydisease (CKD) and consequent end-stage renal failure necessitating renal replacement therapy is threatening to reach epidemic proportions over the next decade, and only a small number of countries have robust economies able to meet the challenges posed. A change in global approach to CKD from treatment of end-stage renal disease (ESRD) to much more aggressive primary and secondary
Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronickidneydisease. The National Kidney Foundation has advocated the use of the abbreviated Modification of Diet in Renal Disease (MDRD) equation to estimate glomerular filtration rate (GFR) from serum creatinine measurements in clinical laboratories. However, healthy persons were not included in the development of the MDRD equation.To assess the accuracy of the MDRD equation in patients (...) with chronickidneydisease compared with healthy persons and to develop a new equation that uses both patients with chronickidneydisease and healthy persons.Cross-sectional study.The Mayo Clinic, a tertiary-care medical center.Consecutive patients (n = 320) who had an iothalamate clearance test specifically for chronickidneydisease evaluation and consecutive healthy persons (n = 580) who had an iothalamate clearance test specifically for kidney donor evaluation.Serum creatinine levels, GFR
Chronickidneydisease and the risks of death, cardiovascular events, and hospitalization. End-stage renal disease substantially increases the risks of death, cardiovascular disease, and use of specialized health care, but the effects of less severe kidney dysfunction on these outcomes are less well defined.We estimated the longitudinal glomerular filtration rate (GFR) among 1,120,295 adults within a large, integrated system of health care delivery in whom serum creatinine had been measured (...) between 1996 and 2000 and who had not undergone dialysis or kidney transplantation. We examined the multivariable association between the estimated GFR and the risks of death, cardiovascular events, and hospitalization.The median follow-up was 2.84 years, the mean age was 52 years, and 55 percent of the group were women. After adjustment, the risk of death increased as the GFR decreased below 60 ml per minute per 1.73 m2 of body-surface area: the adjusted hazard ratio for death was 1.2
The metabolic syndrome and chronickidneydisease in U.S. adults. The metabolic syndrome is a common risk factor for cardiovascular disease.To examine the association between the metabolic syndrome and risk for chronickidneydisease and microalbuminuria.Cross-sectional study.The Third National Health and Nutrition Examination Survey.Participants 20 years of age or older were studied in the chronickidneydisease (n = 6217) and microalbuminuria (n = 6125) analyses.The metabolic syndrome (...) was defined as the presence of 3 or more of the following risk factors: elevated blood pressure, low high-density lipoprotein cholesterol level, high triglyceride level, elevated glucose level, and abdominal obesity. Chronickidneydisease was defined as a glomerular filtration rate less than 60 mL/min per 1.73 m2, and microalbuminuria was defined as a urinary albumin-creatinine ratio of 30 to 300 mg/g.The multivariate-adjusted odds ratios of chronickidneydisease and microalbuminuria in participants
The prevalence of nontraditional risk factors for coronary heart disease in patients with chronickidneydisease. Risk for coronary heart disease is high among patients with chronickidney disease.To compare the prevalence of low apolipoprotein A1 levels and elevated apolipoprotein B, plasma fibrinogen, lipoprotein(a), homocysteine, and C-reactive protein levels by estimated glomerular filtration rate (GFR).Cross-sectional study.Third National Health and Nutrition Examination survey.12 547 (...) homocysteine level of at least 15 micromol/L, and a C-reactive protein level of at least 10.0 mg/L for participants with chronickidneydisease compared with those with a GFR of at least 90 mL/min per 1.73 m2 or greater were 1.92 (95% CI, 1.02 to 3.63), 1.82 (CI, 1.06 to 3.13), 1.74 (CI, 1.35 to 2.24), 8.23 (CI, 5.00 to 13.6), and 1.93 (CI, 1.33 to 2.81), respectively.Levels of apolipoprotein A1 are decreased and levels of homocysteine, lipoprotein(a), fibrinogen, and C-reactive protein are increased among
Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronickidneydisease: a meta-analysis of randomized, controlled trials Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronickidneydisease: a meta-analysis of randomized, controlled trials Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronickidneydisease: a meta-analysis of randomized, controlled trials Alonso A, Lau J, Jaber B L, Weintraub (...) A, Sarnak M J CRD summary This systematic review concluded that N-acetylcysteine is effective in the prevention of renal contrast nephropathy in patients with pre-existing chronickidneydisease. Although there were some limitations of the review in terms of measures taken to minimise reviewer bias and possible statistical diversity, overall, the authors' conclusions appear reliable. Authors' objectives To assess the effects of N-acetylcysteine (NAC) in the prevention of renal contrast nephropathy (RCN
National Kidney Foundation practice guidelines for chronickidneydisease: evaluation, classification, and stratification. Chronickidneydisease is a worldwide public health problem with an increasing incidence and prevalence, poor outcomes, and high cost. Outcomes of chronickidneydisease include not only kidney failure but also complications of decreased kidney function and cardiovascular disease. Current evidence suggests that some of these adverse outcomes can be prevented or delayed (...) by early detection and treatment. Unfortunately, chronickidneydisease is underdiagnosed and undertreated, in part as a result of lack of agreement on a definition and classification of its stages of progression. Recent clinical practice guidelines by the National Kidney Foundation 1) define chronickidneydisease and classify its stages, regardless of underlying cause, 2) evaluate laboratory measurements for the clinical assessment of kidneydisease, 3) associate the level of kidney function
The timing of specialist evaluation in chronickidneydisease and mortality. Care for chronic renal failure involves management of complications and preparation for possible dialysis. Patients often are not evaluated by nephrologists in a timely manner.To identify factors associated with late evaluation by a nephrologist and to assess whether late evaluation is associated with worse survival once patients develop end-stage renal disease (ESRD).National prospective cohort study.81 dialysis (...) characteristics, and socioeconomic status in Cox proportional hazards regression analysis. After additional adjustment for such factors as the presence and severity of comorbid conditions, the association remained graded (hazard ratio, 1.2 [CI, 0.73 to 1.82] for patients evaluated at an intermediate point and 1.6 [CI, 1.04 to 2.39] for those evaluated late).Late evaluation of patients with chronic renal failure by a nephrologist is associated with greater burden and severity of comorbid disease, black